Since the majority of melanoma patients in poorly funded healthcare environments to this day still do not have routine access to costly BRAFV600/MEK inhibitor or immunotherapeutics based treatments, these patients still rely on chemotherapy. The gene discussed is MAP2K7; the disease is melanoma.